Covidien 2.0 – A Conversation With Joe Almeida
Covidien President and CEO Joe Almeida is positioning the company to continue its dynamic growth. Having run up an impressive track record over the past several years, where will – where can-- Covidien go from here?
You may also be interested in...
In late December 2012, Covidien announced a definitive agreement to acquire drug-coated balloon company CV Ingenuity for an undisclosed amount. Covidien joins large cardiovascular device players such as Medtronic, which gained a drug-coated balloon when it acquired Invatec in 2010, and CR Bard, which has the lead in the US market as a result of its acquisition last year of Lutonix Inc. as well as a large number of DCB companies based in Europe.
Renal denervation was clearly the belle of this year’s EuroPCR, with more than a dozen sessions on the topic. In addition, just preceding the meeting, Covidien announced its acquisition of RDN start-up Maya Medical.
Covidien Ltd. continues to build its vascular global business unit with the acquisition of peripheral leader ev3 Inc.